Agenus Inc. (AGEN) Stock Price & Analysis
Agenus Inc. (AGEN) closed at USD 6.33 on Friday, October 23, 2026, down 2.77% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 6.33; the Oct 23, 2026 session ranged USD 6.16–6.5 on volume of 509,035 shares. Market capitalization is —, with a 52-week range of USD 2.71–10.31 (NCM). Source: Nexqual, retrieved October 24, 2026 at 02:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/AGEN.md
Key facts (AGEN)
- Last four reported quarters (through Jun 30, 2026): revenue $133M, net income $91.9M (69.3% margin), free cash flow -$98.5M (SEC filings).
- Total return with dividends: 1Y +52.9% vs S&P 500 +13.4%; 5Y -91.6% vs S&P 500 +76.9%.
- Next earnings: 2026-11-05, EPS estimate USD 0.04, revenue estimate $28.2M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (AGEN)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $296M | $98.0M | $156M | $103M | $114M | $133M |
| Gross profit | $292M | $87.5M | $153M | $103M | $113M | — |
| Operating income | $25.7M | -$179M | -$160M | -$120M | -$20.2M | $36.2M |
| Net income | -$28.7M | -$231M | -$257M | -$232M | -$3.1M | $91.9M |
| EPS (diluted) | -$2.20 | -$15.64 | -$13.75 | -$10.59 | $0.00 | — |
| Free cash flow | -$23.7M | -$228M | -$234M | -$159M | -$77.2M | -$98.5M |
| Gross margin | 98.8% | 89.2% | 98.0% | 99.5% | 99.1% | — |
| Operating margin | 8.7% | -183.0% | -102.1% | -116.4% | -17.7% | 27.3% |
| Net margin | -9.7% | -235.3% | -164.7% | -224.5% | -2.7% | 69.3% |
| Revenue growth | +235.3% | -66.8% | +59.5% | -33.8% | +10.4% | — |
| Cash + short-term investments | $307M | $193M | $76.1M | $40.4M | $3.0M | — |
| Total debt | $13.6M | $13.2M | $12.9M | $33.2M | $44.7M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (AGEN)
Analysts (AGEN)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-22 | Chardan Capital | Maintained | Buy | $40 |
| 2026-10-05 | Chardan Capital | Maintained | Buy | $40 |
| 2026-09-28 | Rodman & Renshaw | Initiated | Buy | $19 |
| 2026-09-18 | Chardan Capital | Initiated | Buy | $40 |
| 2026-08-11 | HC Wainwright & Co. | Target lowered | Buy | $30 → $25 |
| 2026-07-30 | B. Riley Securities | Target raised | Buy | $8 → $14 |
| 2026-07-13 | HC Wainwright & Co. | Target raised | Buy | $23 → $30 |
Total return (dividends reinvested) (AGEN)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +52.9% | -91.6% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | +53.1% | -39.1% |
| Volatility (annualized) | 106.4% | 103.2% |
| Max drawdown | -40.8% (Jan 2026→Feb 2026) | -98.1% (Nov 2021→Mar 2025) |
AGEN revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Non Cash Royalty Revenue Related To The Sale Of Future Royalties | $28.1M | 81.5% | +13.4% |
| Non Cash Royalty Revenue | $28.1M | 81.5% | +13.4% |
| Pre Commercial Product Revenue | $6.4M | 18.5% | — |
| Total revenue | $34.5M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
AGEN suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | GlaxoSmithKline Biologicals | “In 2006, we entered into a license agreement and a supply agreement with GlaxoSmithKline Biologicals, S.A. ("GSK") for the use of QS-21 STIMULON.” |
| Partner | INCYTE CORP (INCY) | “In January 2015, we entered into a collaboration with Incyte to discover, develop, and commercialize novel immuno-therapeutics using our antibody platforms.” |
| Partner | MiNK Therapeutics, Inc. (INKT) | “Furthermore, our ability to generate cash from operations is dependent in part on the success of our licensees and collaboration partners, as well as the likelihood and timing of new strategic licensing and partnering relationships and/or successful development, approval and commercialization of product candidates, including through our antibody programs and platforms, MiNK's adoptive cell therapy programs, and ou…” |
| Partner | Zydus Lifesciences | “In January 2026, we closed our previously announced strategic collaboration with Zydus Lifesciences Ltd. ("Zydus"), including the sale of our Emeryville and Berkeley biologics manufacturing facilities.” |
| Partner | GILEAD SCIENCES, INC. (GILD) | “For example, in February 2015, we began a broad collaboration with Incyte to pursue the discovery and development of antibodies, in December 2018 we entered into a partnership with Gilead relating to five of our antibody programs and in May 2021 we entered into a license agreement with BMS relating to our anti-TIGIT bispecific antibody” |
| Partner | Betta Pharmaceuticals | “In May 2025, we delivered to Betta Pharmaceuticals ("Betta") a notice of termination of the license and collaboration agreement we entered into with them in June 2020.” |
| Partner | Cancer Research | “On December 5, 2014, we entered into a license agreement with the Ludwig Institute for Cancer Research Ltd. ("Ludwig") that replaced and superseded a prior agreement between the parties executed in May 2011.” |
| Partner | UroGen Pharma Ltd. (URGN) | “We have entered into collaborations with several companies, including Bristol-Myers Squibb Company ("BMS"), Betta Pharmaceuticals Co., Ltd. ("Betta"), UroGen Pharma Ltd. ("UroGen"), Gilead Sciences, Inc. ("Gilead"), Incyte Corporation ("Incyte"), and Merck Sharp & Dohme ("Merck").” |
| Partner | Merck (MRK) | “In April 2014, we entered into a collaboration and license agreement with Merck to discover and optimize fully human antibodies against two undisclosed immunotherapy targets.” |
| Partner | LIGAND PHARMACEUTICALS INC (LGND) | “In May 2024, we entered into a Purchase and Sale Agreement with Ligand Pharmaceuticals Incorporated ("Ligand") covering specified economic interests in selected partnered programs and in BOT and BAL.” |
| Partner | Medpace Holdings, Inc. (MEDP) | “On January 10, 2025, we entered into a Payment Agreement with the Medpace, Inc. ("Medpace"), pursuant to which we agreed with Medpace to certain matters related to payments due to Medpace by us under a master services agreement with Medpace dated June 8, 2022.” |
| Partner | SaponiQx | “Furthermore, our ability to generate cash from operations is dependent in part on the success of our licensees and collaboration partners, as well as the likelihood and timing of new strategic licensing and partnering relationships and/or successful development, approval and commercialization of product candidates, including through our antibody programs and platforms, MiNK's adoptive cell therapy programs, and ou…” |
| Partner | Ginkgo Bioworks Holdings, Inc. (DNA) | “In January 2019, we announced that the Bill & Melinda Gates Foundation awarded us a grant to develop an alternative, plant cell culture-based manufacturing process to ensure the continuous future supply of QS-21 STIMULON adjuvant which our subsidiary, SaponiQx, is pursuing in partnership with Phyton Biotech and Ginkgo Bioworks.” |
| Competitor | AbbVie (ABBV) | “These competitors include, but are not limited to, AbbVie, Arcus Biosciences / Gilead Sciences, Alligator Bioscience, AnaptysBio, Astellas Pharma, BeiGene, Bicara Therapeutics, Boehringer Ingelheim, Compass Therapeutics, Compugen, Galapagos NV, Genmab, Innovent Biologics, iTeos Therapeutics, Jacobio Pharmaceuticals, Lokon Pharma, Lyvgen Biopharma, MacroGenics, Mereo BioPharma, Novartis, Oncotelic Therapeutics, Pal…” |
| Competitor | Pfizer (PFE) | “These competitors include, but are not limited to, AbbVie, Arcus Biosciences / Gilead Sciences, Alligator Bioscience, AnaptysBio, Astellas Pharma, BeiGene, Bicara Therapeutics, Boehringer Ingelheim, Compass Therapeutics, Compugen, Galapagos NV, Genmab, Innovent Biologics, iTeos Therapeutics, Jacobio Pharmaceuticals, Lokon Pharma, Lyvgen Biopharma, MacroGenics, Mereo BioPharma, Novartis, Oncotelic Therapeutics, Pal…” |
Quoted from the company's 10-K filed Mar 16, 2026.
Companies that name AGEN in their SEC reports
| Relationship to AGEN | Company | Filing | Sentence |
|---|---|---|---|
| partner | MiNK Therapeutics, Inc. (INKT) | 10-K Mar 31, 2026 | “Our Intellectual Property Assignment and License Agreement with Agenus(September 2021), providing access to a portfolio of immuno-oncology assets and adjuvants to support combination strategies.” |
| partner | UroGen Pharma Ltd. (URGN) | 10-K Mar 2, 2026 | “In November 2025, we decided to discontinue development of UGN-301 based on our strategic priorities and provided Agenus Inc. ("Agenus") notice of termination of the license agreement.” |
| partner | LIGAND PHARMACEUTICALS INC (LGND) | 10-K Feb 27, 2026 | “Building on these results, Agenus, in collaboration with Canadian Cancer Trials Group (CCTG) has initiated the global BATTMAN Phase 3 trial evaluating BOT+BAL versus best supportive care (BSC) in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) colorectal cancer.” |
| partner | INCYTE CORP (INCY) | 10-K Feb 10, 2026 | “In January 2015, we entered into a License, Development and Commercialization Agreement with Agenus Inc. and its wholly-owned subsidiary, 4-Antibody AG (now known as Agenus Switzerland Inc.), which we collectively refer to as Agenus.” |
AGEN customer concentration
In the period ended Dec 31, 2025, a single direct customer accounted for 95% of revenue, per the company's 10-K filed Mar 16, 2026. The company does not name it.
AGEN company outlook (results filed Aug 6, 2026)
- “Based on the company's current operating plan, the upfront proceeds are expected to support ROBBIN initiation, regulatory alignment and company operations through Q3 2027.”
- “Assuming full exercise of the warrants, the financing is expected to support the planned ROBBIN program and company operations through year-end 2031.”
- “Manuscripts with longer-term follow-up from both studies are anticipated in the second half of 2026.”
Quoted word-for-word from the SEC 8-K results press release.
AGEN analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.04 | $0.90 | -95.6% | $28.2M | 1 |
| Next quarter (ends Dec 2026) | $0.04 | $0.00 | — | $28.8M | 1 |
| Current fiscal year (ends Dec 2026) | $0.50 | $0.25 | +100.0% | $125.2M | 1 |
| Next fiscal year (ends Dec 2027) | $-0.11 | $0.00 | — | $116.0M | 1 |
Key Statistics (as of October 24, 2026 at 02:21 UTC)
| Price | USD 6.33 |
|---|---|
| Change | ▼ 2.77% (down) |
| Previous Close | USD 6.33 |
| Open | USD 6.33 |
| Day Range | USD 6.16 – 6.5 |
| 52-Week Range | USD 2.71 – 10.31 |
| Volume | 509,035 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (AGEN)
Nexqual's technical model rates AGEN "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 24, 2026 at 02:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 38.94 (neutral) |
| vs SMA50 | Below (USD 7.67) |
| MACD | -0.44 (negative) |
Earnings (AGEN)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD 0.04 |
| Revenue Estimate | $28.23M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.01 vs est 0.04 ▼ miss |
| 2026-03-31 | USD -0.03 vs est 1.8 ▼ miss |
| 2025-12-31 | USD 0.68 vs est -1.3 ▲ beat |
| 2025-09-30 | USD -1.16 vs est 2.2 ▼ miss |
Source: Nexqual, October 24, 2026 at 02:21 UTC.
Financials & Fundamentals (AGEN)
| Total Revenue | $132.69M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +34.40% |
| Gross Margin | +113.61% |
| Operating Margin | +32.72% |
| Profit Margin | +69.34% |
| Current Ratio | 0.34 |
| Total Cash | $18.74M |
| Total Debt | $40.71M |
Source: Nexqual, October 24, 2026 at 02:21 UTC.
Ownership (AGEN)
| Insider Ownership | +6.27% |
|---|---|
| Institutional Ownership | +46.41% |
| Shares Outstanding | 45.16M |
| Float | 40.23M |
| Short % of Float | +15.28% |
Source: Nexqual, October 24, 2026 at 02:21 UTC.
From Agenus Inc.'s Latest SEC 10-K Filing (filed 2026-03-16)
Key Strengths & Strategy (as disclosed to the SEC)
- In the United States, the FDA under the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act and other federal statutes and regulations, subject pharmaceutical products to rigorous review.
- Through various acquisitions and collaborations, we own, co-own or have exclusive rights to patents and patent applications directed to methods and compositions, including methods for identifying therapeutic antibodies and product candidates arising from our technology platforms.
- We have instituted procedures that we believe will enable us to comply with these requirements and the contractual requirements of our data sources.
Partnerships
- In January 2026, we closed our previously announced strategic collaboration with Zydus Lifesciences Ltd. ("Zydus"), including the sale of our Emeryville and Berkeley biologics manufacturing facilities.
- In May 2021, we entered into a License, Development and Commercialization Agreement with Bristol Myers Squibb ("BMS") under which we granted BMS an exclusive license to develop, manufacture and commercialize our TIGIT bispecific antibody program, AGEN1777.
Legal & Regulatory Risks (Item 1A, quoted)
- The regulatory approval process for our product candidates is uncertain and will be lengthy, and may evolve even after we have engaged with relevant regulatory authorities and selected a regulatory pathway.
- We may fail to obtain regulatory approval of our product candidates.
- Laws and regulations governing any international operations may preclude us from developing, manufacturing and selling certain products outside of the United States and require us to develop and implement costly compliance programs.
- Our ability to use net operating losses and tax credits to offset future income may be subject to limitations.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 303.53 | ▼ 1.39% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 89.27 | ▼ 1.79% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.09 | ▼ 0.35% |
| PRAX | Praxis Precision Medicines, Inc | USD 252.96 | ▼ 2.3% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 42.93 | ▼ 2.23% |
| ABVX | Abivax SA | USD 88.01 | ▼ 2.46% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 02:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt